Shan Yuan, Wang Ping, Liu JingHua
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Medicine (Baltimore). 2018 Dec;97(51):e13613. doi: 10.1097/MD.0000000000013613.
Antiphospholipid syndrome (APS) combined with acute coronary syndrome (ACS) is rarely reported.
One male patient with APS was admitted to our hospital, who had recent unstable angina (UA).
The preliminary diagnosis of ACS and UA (BraunwaldiB) was then made.
This patient received secondary preventative therapy for coronary heart disease (CHD) in combination with percutaneous transluminal coronary angioplasty (PTCA) and implantation of NeoVas Bioresorbable Coronary Scaffold.
The patient was followed up, without new UA episodes were observed at 6 months, 1 year, and 2 year after surgery, respectively.
It was thus concluded that percutaneous coronary intervention (PCI) is effective for APS patients and NeoVas scaffold implantation is presumed safe.
抗磷脂综合征(APS)合并急性冠状动脉综合征(ACS)的报道很少。
一名患有APS的男性患者因近期不稳定型心绞痛(UA)入院。
随后做出了ACS和UA(Braunwald I B)的初步诊断。
该患者接受了冠心病(CHD)二级预防治疗,并结合经皮冠状动脉腔内血管成形术(PTCA)和植入NeoVas生物可吸收冠状动脉支架。
对患者进行随访,术后6个月、1年和2年分别未观察到新的UA发作。
因此得出结论,经皮冠状动脉介入治疗(PCI)对APS患者有效,且NeoVas支架植入被认为是安全的。